

How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?

Valérie Janelle, Alain Lamarre

► **To cite this version:**

Valérie Janelle, Alain Lamarre. How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?. *Frontiers in Oncology*, Frontiers, 2014, 4, pp.135. 10.3389/fonc.2014.00135 . pasteur-01135735

HAL Id: pasteur-01135735

<https://hal-riip.archives-ouvertes.fr/pasteur-01135735>

Submitted on 25 Mar 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



How informative is the immune response against surrogate tumor antigens to assess antitumor immunity?

Valérie Janelle^{1,2} and Alain Lamarre^{1,2*}

¹ Immunovirology Laboratory, Institut National de la Recherche Scientifique, INRS-Institut Armand-Frappier, Laval, QC, Canada

² Department of Biology, Biomed Research Center, Université du Québec à Montréal, Montréal, QC, Canada

*Correspondence: alain.lamarre@iaf.inrs.ca

Edited by:

Philippe Fournier, German Cancer Research Center (DKFZ), Germany

Reviewed by:

Volker Schirmmayer, German Cancer Research Center (DKFZ), Germany

John Cameron Bell, Ottawa Hospital Research Institute, Canada

Keywords: oncolytic viruses, tumor antigens, CD8-positive T-lymphocytes, B16F10, VSV

A commentary on

The strength of the T cell response against a surrogate tumor antigen (TA) induced by oncolytic vesicular stomatitis virus (VSV) therapy does not correlate with tumor control

by Janelle V, Langlois M-P, Lapierre P, Charpentier T, Poliquin L, Lamarre A. *Mol Ther* (2014). doi: 10.1038/mt.2014.34


The last decade has seen the development of numerous antitumor therapeutic approaches. Concomitantly, the interest for using oncolytic viruses (OV) against cancer has grown tremendously and a number of promising candidates are now in pre-clinical and clinical studies. Tumor regression *in vivo* following viral infection has been shown to be a multifactorial process (1). The reductionist view of viruses simply causing direct lysis of infected cancer cells has now been replaced by a view including the complex interplay between viruses and the tumor environment. The important role of the immune response in either limiting or enhancing OV therapy is also now well recognized (2, 3). The prototypic *Rhabdoviridae* VSV has generated encouraging results in various experimental tumor models and is now used in a phase I clinical trial in patients with liver cancer (www.clinicaltrials.gov; #NCT01628640). VSV possesses intrinsic oncolytic properties as it replicates more efficiently in type-I interferon (IFN)-defective cells, a pathway frequently impaired during tumorigenesis (4). Cancer therapy using VSV has been shown to generate a variety of immune

responses including tumor-specific CD8⁺ T cells that are induced following the release of TA by infected cells (5). However, the tumor-specific immune response generated following VSV treatment is usually weak and often only leads to transient tumor control. Experimental tumor models expressing various surrogate non-self-TA have been developed over the years to more easily assess the magnitude and quality of immune responses generated against tumors. However, whether these responses are always representative of physiological antitumor immune responses is unclear.

Recently, our group characterized various VSV glycoprotein (G) mutants capable of interfering with host cell metabolism by inhibiting cellular transcription and translation in a kinetic similar to WT VSV as opposed to the prototypic matrix (M) mutant (M_{M51R}) that is slightly attenuated *in vitro* (6). Furthermore, VSV G mutants proved to be more cytolytic for B16 melanoma cells *in vitro* than the M mutant. To analyze their oncolytic potential *in vivo*, we used an immunocompetent mouse model implanted with B16 tumors transfected with a DNA minigene encoding the immunodominant CD8⁺ T cell epitope of the lymphocytic choriomeningitis virus (glycoprotein aa 33–41) (7) as a surrogate non-self-TA (B16gp33) (8). Mice were injected subcutaneously into the flank with B16gp33 cells and when tumors reached a palpable size (day 7), animals were treated intratumorally every second day with three doses (days 7, 9, and 11) of WT VSV or of the G or M mutants. Tetramer

and intracellular cytokine staining analysis revealed that CD8⁺ T cells harvested from mice treated with WT VSV or the G mutants developed a polyfunctional gp33-specific immune response. Surprisingly however, the strength of the gp33-specific immune response generated did not correlate with the ability of a particular strain of VSV to slow down parental B16 growth and improve mice survival. Treatment with WT VSV was the poorest at controlling B16 tumor progression even though it induced a strong CTL response against gp33. On the other hand, M_{M51R} was more efficient than WT VSV at slowing down B16 growth despite the fact that this virus induced the lowest gp33-specific T cell response. We therefore determined whether CD8⁺ T cell responses directed against endogenous self-TA were involved in limiting tumor progression. CTL responses against self-TA, such as TRP-1 and gp100, were barely detectable *ex vivo* when analyzed separately. However, adoptive transfer of purified CD8⁺ T cells harvested from M_{M51R}-treated B16gp33 melanoma-bearing mice into naive mice provided better protection against parental B16 tumor implantation compared to CTLs taken from WT or G mutant-treated mice. These results suggest that the M mutant, despite being the weakest at inducing a T cell response against the surrogate non-self-TA gp33, induces the broadest antitumoral CTL response.

B16 melanoma is a highly aggressive tumor model in part because major histocompatibility complex class I (MHC-I) surface expression is very low on these



cells. Strikingly, B16 infection with VSV M mutant induced the upregulation of surface MHC-I both *in vitro* and *in vivo*, a phenomenon that was not observed for WT VSV of the G mutants (8). The matrix protein of VSV was previously shown to alter trafficking of a molecule structurally similar to MHC-I, namely CD1d (9, 10). This leads to inhibition of antigen presentation to natural killer T (NKT) cells (11). Thus, VSV matrix protein could participate in the retention of MHC-I molecules within infected cells while the mutated protein in M_{M51R} may lack this ability. Thus, surface MHC-I upregulation following M_{M51R} treatment likely explains the significantly improved CD8⁺ T cell-dependent survival despite the poor gp33-specific CTL response induced by this mutant. This may subsequently lead to presentation of a broader pool of B16 TA proportionally reducing the response against gp33 (see **Figure 1** for model).

In a recent study, Pedersen et al. compared vaccine-induced CD8⁺ T cell responses directed against self and non-self-TA and showed that vaccination with

adenoviral vectors encoding endogenous TA had little or no effect on the growth of B16 melanomas whereas vaccination with a similar vector construct expressing a surrogate non-self-TA induced efficient tumor control (12). Although vaccination against both self and non-self-TA induced comparable CD8⁺ T cell responses in terms of cell numbers and effector functions, CTLs directed against self-TA were of lower functional avidity. These results are in agreement with our study and provide a potential mechanism explaining why T cell responses against self and non-self-TA are different and might not be induced at proportional levels during OV therapy.

Taken together, these results highlight a considerable limitation of many experimental systems used to assess antitumor immunity and warrant caution when extrapolating responses against surrogate TA to the overall antitumoral immune response. This may prove critical for the development of novel or improved OV, which may be biased by incorrectly estimating immune response correlates using such experimental systems. Therefore,

great efforts will need to be made to develop improved methods for analyzing the antitumoral immune response induced by OVs against a broader array of TA in order to better appreciate their full therapeutic potential.

ACKNOWLEDGMENTS

This work was supported by the Canadian Institutes of Health Research and by the J.-Louis Lévesque Foundation.

REFERENCES

1. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. *Cytokine Growth Factor Rev* (2010) 21(2–3):127–34. doi:10.1016/j.cytogfr.2010.02.014
2. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. *Gene Ther* (2010) 17(2):158–70. doi:10.1038/gt.2009.161
3. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. *Hum Gene Ther* (2009) 20(10):1119–32. doi:10.1089/hum.2009.135
4. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune

- signaling pathways. *Expert Opin Biol Ther* (2009) **9**(9):1163–76. doi:10.1517/14712590903170653
5. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. *Cancer Res* (2007) **67**(6):2840–8. doi:10.1158/0008-5472.CAN-06-3974
 6. Janelle V, Brassard F, Lapierre P, Lamarre A, Poliquin L. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. *J Virol* (2011) **85**(13):6513–20. doi:10.1128/JVI.02484-10
 7. Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. *J Immunol* (1998) **161**(5):2187–94.
 8. Janelle V, Langlois M-P, Lapierre P, Charpentier T, Poliquin L, Lamarre A. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. *Mol Ther* (2014). doi:10.1038/mt.2014.34
 9. Calabi F, Bradbury A. The CD1 system. *Tissue Antigens* (1991) **37**(1):1–9. doi:10.1111/j.1399-0039.1991.tb01836.x
 10. Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A. TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. *J Exp Med* (1995) **182**(6):1913–9. doi:10.1084/jem.182.6.1913
 11. Renukaradhya GJ, Khan MA, Shaji D, Brutkiewicz RR. Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. *J Virol* (2008) **82**(24):12535–42. doi:10.1128/JVI.00881-08
 12. Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. *J Immunol* (2013) **191**(7):3955–67. doi:10.4049/jimmunol.1300555
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Received: 13 March 2014; accepted: 21 May 2014; published online: 04 June 2014.
- Citation: Janelle V and Lamarre A (2014) How informative is the immune response against surrogate tumor antigens to assess antitumor immunity? *Front. Oncol.* **4**:135. doi: 10.3389/fonc.2014.00135
- This article was submitted to *Tumor Immunity*, a section of the journal *Frontiers in Oncology*.
- Copyright © 2014 Janelle and Lamarre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.